A citation-based method for searching scientific literature

Josep Tabernero, Paulo M Hoff, Lin Shen, Atsushi Ohtsu, Manish A Shah, Karen Cheng, Chunyan Song, Haiyan Wu, Jennifer Eng-Wong, Katherine Kim, Yoon-Koo Kang. Lancet Oncol 2018
Times Cited: 204



E C Smyth, M Verheij, W Allum, D Cunningham, A Cervantes, D Arnold. Ann Oncol 2016
Times Cited: 835




List of shared articles



Times cited


Current status and future perspectives in HER2 positive advanced gastric cancer.
G Roviello, M Catalano, L F Iannone, L Marano, M Brugia, G Rossi, G Aprile, L Antonuzzo. Clin Transl Oncol 2022
1

Chemorefractory Gastric Cancer: The Evolving Terrain of Third-Line Therapy and Beyond.
Maria Alsina, Josep Tabernero, Marc Diez. Cancers (Basel) 2022
1

Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer.
Nicole M Myer, Kohei Shitara, Hyun C Chung, Florian Lordick, Ronan J Kelly, Zsolt Szabo, Z Alexander Cao, Stephen Leong, David H Ilson, Wilko Weichert. J Cancer Res Clin Oncol 2022
0

The HIF-1α as a Potent Inducer of the Hallmarks in Gastric Cancer.
Cemre Ucaryilmaz Metin, Gulnihal Ozcan. Cancers (Basel) 2022
0

Resistance mechanisms to HER2-targeted therapy in gastroesophageal adenocarcinoma: A systematic review.
Dionne Blangé, Charlotte I Stroes, Sarah Derks, Maarten F Bijlsma, Hanneke W M van Laarhoven. Cancer Treat Rev 2022
1

HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma.
Josep Tabernero, Lin Shen, Elena Elimova, Geoffrey Ku, Tianshu Liu, Kohei Shitara, Xiao Lin, Lisa Boyken, Huiyan Li, Jonathan Grim,[...]. Future Oncol 2022
0

European-Australasian consensus on the management of advanced gastric and gastro-oesophageal junction cancer: current practice and new directions.
Nick Pavlakis, Gary Tincknell, Lisi Elizabeth Lim, Kei Muro, Radka Obermannova, Sylvie Lorenzen, Yu Jo Chua, Chris Jackson, Christos Stelios Karapetis, Timothy Price,[...]. Ther Adv Med Oncol 2022
0

First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811.
Hyun Cheol Chung, Yung-Jue Bang, Charles S Fuchs, Shu-Kui Qin, Taroh Satoh, Kohei Shitara, Josep Tabernero, Eric Van Cutsem, Maria Alsina, Zhu Alexander Cao,[...]. Future Oncol 2021
50

Changes in the therapeutic landscape of oesophago-gastric cancers.
Nina Fokter Dovnik, Elizabeth C Smyth. Curr Opin Oncol 2021
0

Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand?
Giandomenico Roviello, Giuseppe Aprile, Alberto D'Angelo, Luigi Francesco Iannone, Franco Roviello, Karol Polom, Enrico Mini, Martina Catalano. Gastric Cancer 2021
6

Synergistic antitumor effect of the anti-ErbB2 antibodies trastuzumab and H2-18 on trastuzumab-resistant gastric cancer cells.
Chao Wang, Lingfei Wang, Beibei Liang, Bo Zhou, Yu Sun, Yanchun Meng, Jian Dong, Lin Chen, Bohua Li. Oncol Lett 2021
1

Trastuzumab deruxtecan for the treatment of HER2-positive gastric cancer.
Saori Mishima, Kohei Shitara. Expert Opin Biol Ther 2021
2

Bone Metastases from Gastric Cancer: What We Know and How to Deal with Them.
Angelica Petrillo, Emilio Francesco Giunta, Annalisa Pappalardo, Davide Bosso, Laura Attademo, Cinzia Cardalesi, Anna Diana, Antonietta Fabbrocini, Teresa Fabozzi, Pasqualina Giordano,[...]. J Clin Med 2021
4

Hopes and failures in front-line advanced HER2-positive gastric cancer therapy.
Fanming Kong, Yang Yao, Renfen Deng, Xiaojiang Li, Yingjie Jia. Anticancer Drugs 2021
0

Targeted and immunotherapy in the era of personalised gastric cancer treatment.
Silvia Catanese, Florian Lordick. Best Pract Res Clin Gastroenterol 2021
7

A Phase II Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab and Chemoradiotherapy in the Adjuvant Setting in Operated Patients With HER2-positive Gastric or Gastroesophageal Junction Cancer (TOXAG Study): A Turkish Oncology Group Study.
Huseyin Abali, Suayib Yalcin, Huseyin C Onal, Faysal Dane, Berna Oksuzoglu, Nuriye Ozdemir, Huseyin Mertsoylu, Mehmet Artac, Celaletdin Camci, Bulent Karabulut,[...]. Am J Clin Oncol 2021
6